<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37298447</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>30</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Galectin-3 Mediates NETosis and Acts as an Autoantigen in Systemic Lupus Erythematosus-Associated Diffuse Alveolar Haemorrhage.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9493</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24119493</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with enhanced NETosis and impaired degradation of neutrophil extracellular traps (NETs). Galectin-3 is a &#x3b2;-galactoside binding protein and is associated with neutrophil functions as well as involved in mediating autoimmune disorders. In this study, we plan to examine the associations of galectin-3 with the pathogenesis of SLE and NETosis. Galectin-3 expression levels were determined in peripheral blood mononuclear cells (PBMCs) of SLE patients for the association with lupus nephritis (LN) or correlation of SLE disease activity index 2000 (SLEDAI-2K). NETosis was observed in human normal and SLE and murine galectin-3 knockout (Gal-3 KO) neutrophils. Gal-3 KO and wild-type (WT) mice induced by pristane were used to evaluate disease signs, including diffuse alveolar haemorrhage (DAH), LN, proteinuria, anti-ribonucleoprotein (RNP) antibody, citrullinated histone 3 (CitH3) levels, and NETosis. Galectin-3 levels are higher in PBMCs of SLE patients compared with normal donors and positively correlated with LN or SLEDAI-2K. Gal-3 KO mice have higher percent survival and lower DAH, LN proteinuria, and anti-RNP antibody levels than WT mice induced by pristane. NETosis and citH3 levels are reduced in Gal-3 KO neutrophils. Furthermore, galectin-3 resides in NETs while human neutrophils undergo NETosis. Galectin-3-associated immune complex deposition can be observed in NETs from spontaneously NETotic cells of SLE patients. In this study, we provide clinical relevance of galectin-3 to the lupus phenotypes and the underlying mechanisms of galectin-3-mediated NETosis for developing novel therapeutic strategies targeting galectin-3 for SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shih-Yao</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Nursing, College of Nursing, Chung Hwa University of Medical Technology, Tainan 71703, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chung-Teng</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ching-Yi</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Pin-Yu</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chrong-Reen</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, National Cheng Kung University Hospital, Tainan 70403, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiau</LastName><ForeName>Ai-Li</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0003-2449-8547</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ditmanson Medical Foundation Chia-Yi Christian Hospital, Zhongxiao Road 539, East District, Chiayi 60002, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Cheng-Hsi</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chao-Liang</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0001-7821-9406</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ditmanson Medical Foundation Chia-Yi Christian Hospital, Zhongxiao Road 539, East District, Chiayi 60002, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOST 106-2320-B-006-074</GrantID><Agency>National Science and Technology Council</Agency><Country/></Grant><Grant><GrantID>R111-045</GrantID><Agency>Ditmanson Medical Foundation Chia-Yi Christian Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037502">Galectin 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>26HZV48DT1</RegistryNumber><NameOfSubstance UI="C009042">pristane</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C428445">LGALS3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485095">Lgals3 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065206" MajorTopicYN="Y">Extracellular Traps</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D037502" MajorTopicYN="N">Galectin 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011507" MajorTopicYN="N">Proteinuria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NETosis</Keyword><Keyword MajorTopicYN="N">diffuse alveolar haemorrhage</Keyword><Keyword MajorTopicYN="N">galectin-3</Keyword><Keyword MajorTopicYN="N">neutrophil extracellular traps</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37298447</ArticleId><ArticleId IdType="pmc">PMC10253376</ArticleId><ArticleId IdType="doi">10.3390/ijms24119493</ArticleId><ArticleId IdType="pii">ijms24119493</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos G.C., Lo M.S., Reis P.C., Sullivan K.E. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 2016;12:716&#x2013;730. doi: 10.1038/nrrheum.2016.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava A., Petri M. Systemic lupus erythematosus: Diagnosis and management. J. Autoimmun. 2019;96:i1&#x2013;i13. doi: 10.1016/j.jaut.2018.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.11.001</ArticleId><ArticleId IdType="pmc">PMC6310637</ArticleId><ArticleId IdType="pubmed">30448290</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnarsson I., Sundelin B., J&#xf3;nsd&#xf3;ttir T., Jacobson S.H., Henriksson E.W., van Vollenhoven R.F. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007;56:1263&#x2013;1272. doi: 10.1002/art.22505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22505</ArticleId><ArticleId IdType="pubmed">17393458</ArticleId></ArticleIdList></Reference><Reference><Citation>Mysler E.F., Spindler A.J., Guzman R., Bijl M., Jayne D., Furie R.A., Houssiau F.A., Drappa J., Close D., Maciuca R. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65:2368&#x2013;2379. doi: 10.1002/art.38037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38037</ArticleId><ArticleId IdType="pubmed">23740801</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao V., Gordon C. Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus. Immunotherapy. 2014;6:1165&#x2013;1175. doi: 10.2217/imt.14.80.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt.14.80</ArticleId><ArticleId IdType="pubmed">25496332</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies R., Sangle S., Jordan N., Aslam L., Lewis M., Wedgwood R., D&#x2019;Cruz D. Rituximab in the treatment of resistant lupus nephritis: Therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 2013;22:574&#x2013;582. doi: 10.1177/0961203313483376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313483376</ArticleId><ArticleId IdType="pubmed">23632989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan M.J., Radic M. Neutrophil extracellular traps: Double-edged swords of innate immunity. J. Immunol. 2012;189:2689&#x2013;2695. doi: 10.4049/jimmunol.1201719.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1201719</ArticleId><ArticleId IdType="pmc">PMC3439169</ArticleId><ArticleId IdType="pubmed">22956760</ArticleId></ArticleIdList></Reference><Reference><Citation>Branzk N., Papayannopoulos V. Molecular mechanisms regulating NETosis in infection and disease. Semin. Immunopathol. 2013;35:513&#x2013;530. doi: 10.1007/s00281-013-0384-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-013-0384-6</ArticleId><ArticleId IdType="pmc">PMC3685711</ArticleId><ArticleId IdType="pubmed">23732507</ArticleId></ArticleIdList></Reference><Reference><Citation>Casciola-Rosen L.A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 1994;179:1317&#x2013;1330. doi: 10.1084/jem.179.4.1317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.179.4.1317</ArticleId><ArticleId IdType="pmc">PMC2191465</ArticleId><ArticleId IdType="pubmed">7511686</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz L., Gaipl U., Franz S., Sheriff A., Voll R., Kalden J., Herrmann M. SLE&#x2014;A disease of clearance deficiency? Rheumatology. 2005;44:1101&#x2013;1107. doi: 10.1093/rheumatology/keh693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh693</ArticleId><ArticleId IdType="pubmed">15928001</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva E., Yalavarthi S., Berthier C.C., Hodgin J.B., Khandpur R., Lin A.M., Rubin C.J., Zhao W., Olsen S.H., Klinker M. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 2011;187:538&#x2013;552. doi: 10.4049/jimmunol.1100450.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1100450</ArticleId><ArticleId IdType="pmc">PMC3119769</ArticleId><ArticleId IdType="pubmed">21613614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh Y.T., Chou Y.C., Kuo P.Y., Tsai H.W., Yen Y.T., Shiau A.L., Wang C.R. Down-regulated miR-146a expression with increased neutrophil extracellular traps and apoptosis formation in autoimmune-mediated diffuse alveolar hemorrhage. J. Biomed. Sci. 2022;29:62. doi: 10.1186/s12929-022-00849-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-022-00849-4</ArticleId><ArticleId IdType="pmc">PMC9413930</ArticleId><ArticleId IdType="pubmed">36028828</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman H. The LE cell phenomenon. Annu. Rev. Med. 1960;11:231&#x2013;242. doi: 10.1146/annurev.me.11.020160.001311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.me.11.020160.001311</ArticleId><ArticleId IdType="pubmed">14402754</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabi I.R., Shankar J., Dennis J.W. The galectin lattice at a glance. J. Cell Sci. 2015;128:2213&#x2013;2219. doi: 10.1242/jcs.151159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.151159</ArticleId><ArticleId IdType="pubmed">26092931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang E., Moon K., Lee E., Lee Y., Lee E., Ahn C., Song Y. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus. 2009;18:22&#x2013;28. doi: 10.1177/0961203308094361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203308094361</ArticleId><ArticleId IdType="pubmed">19074165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Y., Lee D.-Y., Lee S., Park S.-Y., Kim J., Cho B., Lee H., Kim H.-Y., Lee E., Song Y.W. Identification of autoantibodies associated with systemic lupus erythematosus. Biochem. Biophys. Res. Commun. 2002;295:119&#x2013;124. doi: 10.1016/S0006-291X(02)00637-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(02)00637-X</ArticleId><ArticleId IdType="pubmed">12083777</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z.R., Tan G.Z., Meng Z., Yu M., Li Kw Yin J., Wei K.H., Luo Y.J., Jia S.Q., Zhang S.J. Association of Anti&#x2013;Acidic Ribosomal Protein P0 and Anti&#x2013;Galectin 3 Antibodies with the Development of Skin Lesions in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2015;67:193&#x2013;203. doi: 10.1002/art.38891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38891</ArticleId><ArticleId IdType="pubmed">25307291</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S., Ouellet N., Pelletier I., Simard M., Rancourt A., Bergeron M.G. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J. Immunol. 2002;168:1813&#x2013;1822. doi: 10.4049/jimmunol.168.4.1813.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.4.1813</ArticleId><ArticleId IdType="pubmed">11823514</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand C., da Costa T.P., Bernardes E.S., Machado C.M.L., Andrade L.R., Chammas R., de Oliveira F.L., El-Cheikh M.C. Differential development of oil granulomas induced by pristane injection in galectin-3 deficient mice. BMC Immunol. 2015;16:68. doi: 10.1186/s12865-015-0133-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-015-0133-9</ArticleId><ArticleId IdType="pmc">PMC4647586</ArticleId><ArticleId IdType="pubmed">26572128</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves C., Silva D., Azzolini A., Marzocchi-Machado C., Lucisano-Valim Y., Roque-Barreira M., Mineo J. Galectin-3 is essential for reactive oxygen species production by peritoneal neutrophils from mice infected with a virulent strain of Toxoplasma gondii. Parasitology. 2013;140:210&#x2013;219. doi: 10.1017/S0031182012001473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0031182012001473</ArticleId><ArticleId IdType="pubmed">22975147</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaoka A., Kuwabara I., Frigeri L.G., Liu F.-T. A human lectin, galectin-3 (epsilon bp/Mac-2), stimulates superoxide production by neutrophils. J. Immunol. 1995;154:3479&#x2013;3487. doi: 10.4049/jimmunol.154.7.3479.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.154.7.3479</ArticleId><ArticleId IdType="pubmed">7897228</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves W.H., Lee P.Y., Weinstein J.S., Satoh M., Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009;30:455&#x2013;464. doi: 10.1016/j.it.2009.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2009.06.003</ArticleId><ArticleId IdType="pmc">PMC2746238</ArticleId><ArticleId IdType="pubmed">19699150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu D.K., Yang R.-Y., Pan Z., Yu L., Salomon D.R., Fung-Leung W.-P., Liu F.-T. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am. J. Pathol. 2000;156:1073&#x2013;1083. doi: 10.1016/S0002-9440(10)64975-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64975-9</ArticleId><ArticleId IdType="pmc">PMC1876862</ArticleId><ArticleId IdType="pubmed">10702423</ArticleId></ArticleIdList></Reference><Reference><Citation>Montiel J., Monsivais-Urenda A., Figueroa-Vega N., Moctezuma J., Burgos-Vargas R., Gonzalez-Amaro R., Rosenstein Y. Anti-CD43 and anti-galectin-1 autoantibodies in patients with systemic lupus erythematosus. Scand. J. Rheumatol. 2010;39:50&#x2013;57. doi: 10.3109/03009740903013213.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009740903013213</ArticleId><ArticleId IdType="pubmed">20132071</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S., Wang Y., Meng Y., Xiao C., Liu Z., Brohawn P., Higgs B.W., Jallal B., Jia Q., Qu B. In vivo therapeutic success of microRNA-155 antagomir in a mouse model of lupus alveolar hemorrhage. Arthritis Rheumatol. 2016;68:953&#x2013;964. doi: 10.1002/art.39485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39485</ArticleId><ArticleId IdType="pubmed">26556607</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccavo D., Rigon A., Picardi A., Galluzzo S., Vadacca M., Ferri G.M., Amoroso A., Afeltra A. Anti-lactoferrin antibodies in systemic lupus erythematosus: Isotypes and clinical correlates. Clin. Rheumatol. 2005;24:381&#x2013;387. doi: 10.1007/s10067-004-1040-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-004-1040-2</ArticleId><ArticleId IdType="pubmed">15592902</ArticleId></ArticleIdList></Reference><Reference><Citation>Spronk P., Bootsma H., Horst G., Huitema M., Limburg P., Tervaert J.C., Kallenberg C. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Rheumatology. 1996;35:625&#x2013;631. doi: 10.1093/rheumatology/35.7.625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/35.7.625</ArticleId><ArticleId IdType="pubmed">8670594</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;ssberger L., Jonsson H., Sjoholm A., Sturfelt G., Heubner A. Circulating anti-elastase in systemic lupus erythematosus. Lancet. 1989;333:509. doi: 10.1016/S0140-6736(89)91420-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(89)91420-7</ArticleId><ArticleId IdType="pubmed">2563889</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch X., Guilabert A., Font J. Antineutrophil cytoplasmic antibodies. Lancet. 2006;368:404&#x2013;418. doi: 10.1016/S0140-6736(06)69114-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)69114-9</ArticleId><ArticleId IdType="pubmed">16876669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessenbrock K., Krumbholz M., Sch&#xf6;nermarck U., Back W., Gross W.L., Werb Z., Gr&#xf6;ne H.-J., Brinkmann V., Jenne D.E. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 2009;15:623&#x2013;625. doi: 10.1038/nm.1959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1959</ArticleId><ArticleId IdType="pmc">PMC2760083</ArticleId><ArticleId IdType="pubmed">19448636</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny M.F., Yalavarthi S., Zhao W., Thacker S.G., Anderson M., Sandy A.R., McCune W.J., Kaplan M.J. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J. Immunol. 2010;184:3284&#x2013;3297. doi: 10.4049/jimmunol.0902199.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0902199</ArticleId><ArticleId IdType="pmc">PMC2929645</ArticleId><ArticleId IdType="pubmed">20164424</ArticleId></ArticleIdList></Reference><Reference><Citation>Leffler J., Martin M., Gullstrand B., Tyd&#xe9;n H., Lood C., Truedsson L., Bengtsson A.A., Blom A.M. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J. Immunol. 2012;188:3522&#x2013;3531. doi: 10.4049/jimmunol.1102404.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102404</ArticleId><ArticleId IdType="pubmed">22345666</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., Meller S., Chamilos G., Sebasigari R., Riccieri V. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA&#x2013;peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 2011;3:73ra19. doi: 10.1126/scitranslmed.3001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001180</ArticleId><ArticleId IdType="pmc">PMC3399524</ArticleId><ArticleId IdType="pubmed">21389263</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., Punaro M., Baisch J., Guiducci C., Coffman R.L. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 2011;3:73ra20. doi: 10.1126/scitranslmed.3001201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001201</ArticleId><ArticleId IdType="pmc">PMC3143837</ArticleId><ArticleId IdType="pubmed">21389264</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkaya H.&#xdc;., Y&#x131;lmaz H.E., Narin F., Sa&#x11f;lam M. Evaluation of galectin-3, peptidylarginine deiminase-4, and tumor necrosis factor-&#x3b1; levels in gingival crevicular fluid for periodontal health, gingivitis, and Stage III Grade C periodontitis: A pilot study. J. Periodontol. 2022;93:80&#x2013;88. doi: 10.1002/JPER.21-0137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JPER.21-0137</ArticleId><ArticleId IdType="pubmed">33913157</ArticleId></ArticleIdList></Reference><Reference><Citation>Beccaria C.G., Amezcua Vesely M.C., Fiocca Vernengo F., Gehrau R.C., Ramello M.C., Tosello Boari J., Gorosito Serran M., Mucci J., Piaggio E., Campetella O. Galectin-3 deficiency drives lupus-like disease by promoting spontaneous germinal centers formation via IFN-&#x3b3;. Nat. Commun. 2018;9:1628. doi: 10.1038/s41467-018-04063-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04063-5</ArticleId><ArticleId IdType="pmc">PMC5915532</ArticleId><ArticleId IdType="pubmed">29691398</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.-C., Chou Y.-C., Hsieh Y.-T., Kuo P.-Y., Yang M.-L., Chong H.-E., Wu C.-L., Shiau A.-L., Wang C.-R. Targeting Intra-Pulmonary P53-Dependent Long Non-Coding RNA Expression as a Therapeutic Intervention for Systemic Lupus Erythematosus-Associated Diffuse Alveolar Hemorrhage. Int. J. Mol. Sci. 2021;22:6948. doi: 10.3390/ijms22136948.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22136948</ArticleId><ArticleId IdType="pmc">PMC8268786</ArticleId><ArticleId IdType="pubmed">34203338</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrot P.-A., Tellier E., Plantureux L., Crescence L., Robert S., Chareyre C., Daniel L., Secq V., Garcia S., Dignat-George F. Neutrophil extracellular traps are associated with the pathogenesis of diffuse alveolar hemorrhage in murine lupus. J. Autoimmun. 2019;100:120&#x2013;130. doi: 10.1016/j.jaut.2019.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.03.009</ArticleId><ArticleId IdType="pubmed">30930069</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumurkhuu G., Laguna D.E., Moore R.E., Contreras J., Santos G.D.L., Akaveka L., Montano E.N., Wang Y., Ishimori M., Venuturupalli S. Neutrophils contribute to ER stress in lung epithelial cells in the pristane-induced diffuse alveolar hemorrhage mouse model. Front. Immunol. 2022;13:790043. doi: 10.3389/fimmu.2022.790043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.790043</ArticleId><ArticleId IdType="pmc">PMC8850275</ArticleId><ArticleId IdType="pubmed">35185885</ArticleId></ArticleIdList></Reference><Reference><Citation>Vats R., Kaminski T.W., Brzoska T., Leech J.A., Tutuncuoglu E., Katoch O., Jonassaint J., Tejero J., Novelli E.M., Pradhan-Sundd T., et al. Liver-to-lung microembolic NETs promote gasdermin D-dependent inflammatory lung injury in sickle cell disease. Blood. 2022;140:1020&#x2013;1037. doi: 10.1182/blood.2021014552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021014552</ArticleId><ArticleId IdType="pmc">PMC9437711</ArticleId><ArticleId IdType="pubmed">35737916</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D.D., Iba&#xf1;ez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 2002;29:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>